Maryland HB838 regulates prescriber-pharmacist agreements for drug therapy management.

Maryland HB838 establishes rules for prescriber-pharmacist agreements, allowing pharmacists to manage drug therapy under specific protocols. These agreements can authorize pharmacists to treat opioid use disorders with controlled substances, provided they meet certain criteria. The bill mandates that pharmacists request data from the Prescription Drug Monitoring Program before initiating or modifying controlled substance therapies. It also requires pharmacists to submit agreements and modifications to the Board of Pharmacy. The provisions take effect July 1, 2026.

Maryland HB838 regulates prescriber-pharmacist agreements for drug therapy management.

Maryland HB838 establishes rules for prescriber-pharmacist agreements, allowing pharmacists to manage drug therapy under specific protocols. These agreements can authorize pharmacists to treat opioid use disorders with controlled substances, provided they meet certain criteria. The bill mandates that pharmacists request data from the Prescription Drug Monitoring Program before initiating or modifying controlled substance therapies. It also requires pharmacists to submit agreements and modifications to the Board of Pharmacy. The provisions take effect July 1, 2026.